News

Orsini Launches ORBIT AI Platform to Help Patients with Rare Diseases

• By John K. Waters
• 10/09/2024

Orsini, which specializes in providing pharmacy solutions for rare disease and complex therapy programs, has announced the launch of ORBIT (Orsini Rare Business Intelligence Technology), a new AI-enabled reporting and analytics platform aimed at transforming patient care for individuals living with rare diseases. ORBIT was developed to provide critical insights that cater to the unique needs of those with rare conditions.

ORBIT leverage AI to empower manufacturers and healthcare stakeholders to gain deeper insights through real-world data and robust analytics, the company said, allowing for more personalized patient care. The platform’s core objective is to enable more informed decision-making, enhance patient engagement, and drive adherence to treatment plans, all while creating a more customized experience for each patient, the company said.

ORBIT's flexibility stems from its API-forward design, which allows it to integrate seamlessly with various systems, including pharmacy, patient engagement platforms, and manufacturers' networks. This real-time data exchange capability is designed to foster a highly connected ecosystem, which is crucial in rare disease care where patient needs are often complex and multifaceted.

"As the name suggests, ORBIT revolves around the patient, collecting and analyzing data to deliver a personalized experience," said Ashok Singh, Chief Information Officer at Orsini, in a statement. Singh, who joined the company in April, has spearheaded technology enhancements at Orsini; ORBIT is the first in a series of AI-driven initiatives from the company aimed at improving rare disease patient care. "This flexible, first-of-its-kind platform harnesses the power of AI to deliver better outcomes in rare disease care," Singh said.

ORBIT's key innovation lies in its ability to merge real-world data with cutting-edge analytics to help pharmaceutical manufacturers better understand the needs of rare disease patients. The platform not only offers comprehensive reporting but also helps predict patient behavior, the company said, providing the personalized support necessary to ensure adherence and optimize treatment outcomes.

Orsini's care model includes therapy care teams that provide personalized support, focusing on hands-on engagement with patients. The company integrates pharmacy distribution, patient services, clinical management, and home infusion services in collaboration with biopharma innovators, healthcare providers, and payors, aimed at facilitating access to treatments for individuals with rare diseases.

The launch of ORBIT comes at a critical time, as the rare disease market continues to grow, with thousands of patients worldwide relying on specialized therapies. Pharmaceutical companies increasingly look to data-driven solutions to manage the unique challenges posed by rare conditions, including small patient populations, complex treatment regimens, and the need for continuous monitoring.